ImageneBio Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $62.5M
- Price
- $5.51
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.78%
- Volume
- 19.9K
About
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Quick stats
Shares outstanding11.4M
Computed float9.0M
Float / shares79.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835579
Websitehttps://imagenebio.com
AI Summary
AI-generated1/8
minorbullishoperations update
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio granted inducement awards to new employees, including Chief Financial Officer Yanina Grant-Huerta and three non-executive employees, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards consist of 144,000 RSUs and 112,525 NSOs granted as employment inducements, with the CFO receiving an additional 39,000 RSUs under the company's 2025 Equity Incentive Plan.
Options have an exercise price of $5.84 per share, equal to the closing price on the grant date, and vest over four years subject to continuous service.